


## Eprinomectin

<b>Cat. No.:</b>	HY-12643												
<b>CAS No.:</b>	123997-26-2												
<b>Molecular Formula:</b>	C <sub>50</sub> H <sub>75</sub> NO <sub>14</sub>												
<b>Molecular Weight:</b>	914.13												
<b>Target:</b>	Parasite; Bacterial; Reactive Oxygen Species; β-catenin; Apoptosis; Autophagy												
<b>Pathway:</b>	Anti-infection; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB; Stem Cell/Wnt; Apoptosis; Autophagy												
<b>Storage:</b>	<table border="0"> <tr> <td>Powder</td> <td>-20°C</td> <td>3 years</td> </tr> <tr> <td></td> <td>4°C</td> <td>2 years</td> </tr> <tr> <td>In solvent</td> <td>-80°C</td> <td>6 months</td> </tr> <tr> <td></td> <td>-20°C</td> <td>1 month</td> </tr> </table>	Powder	-20°C	3 years		4°C	2 years	In solvent	-80°C	6 months		-20°C	1 month
Powder	-20°C	3 years											
	4°C	2 years											
In solvent	-80°C	6 months											
	-20°C	1 month											



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 125 mg/mL (136.74 mM; Need ultrasonic)				
		Solvent Concentration	Mass		
	<b>Preparing Stock Solutions</b>		1 mg	5 mg	10 mg
		1 mM	1.0939 mL	5.4697 mL	10.9394 mL
		5 mM	0.2188 mL	1.0939 mL	2.1879 mL
	10 mM	0.1094 mL	0.5470 mL	1.0939 mL	
Please refer to the solubility information to select the appropriate solvent.					
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (2.73 mM); Clear solution				
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.5 mg/mL (2.73 mM); Suspended solution; Need ultrasonic				
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (2.73 mM); Clear solution				

### BIOLOGICAL ACTIVITY

<b>Description</b>	Eprinomectin (MK-397) is a type of avermectin. Eprinomectin, as a broad-spectrum fungicide, has insecticidal, insecticidal and acaricidal activities. Eprinomectin induces apoptosis and autophagy in prostate cancer cells and has antitumor activity [1][2][3].
<b>IC<sub>50</sub> &amp; Target</b>	Mite

**In Vitro**

Eprinomectin (2.5-50  $\mu\text{M}$ ; 0-48 h) significantly inhibits DU145 cell viability ( $\text{IC}_{50}$ : 12.5  $\mu\text{M}$ ), colony formation and migration ability, and induces G0/G1 phase cell cycle arrest<sup>[1]</sup>.

Eprinomectin (10-50  $\mu\text{M}$ ; 48 h) induces apoptosis and autophagy, increases the production of reactive oxygen species and endoplasmic reticulum stress, and promotes  $\beta$ -catenin nucleoplasmic translocation in DU145 cells<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay<sup>[1]</sup>

Cell Line:	DU145 cells
Concentration:	2.5, 5, 10, 25 and 50 $\mu\text{M}$
Incubation Time:	48 h
Result:	Significantly inhibited the cell viability.

Western Blot Analysis<sup>[1]</sup>

Cell Line:	DU145 cells
Concentration:	10, 25 and 50 $\mu\text{M}$
Incubation Time:	48 h
Result:	Promoted the protein expression of the pro-apoptotic marker BAD and DNA damage marker pH2AX as well as caspase-9 in a concentration-dependent manner. Inhibited DNA repair by decreasing PARP-1.

**In Vivo**

Eprinomectin (0.08-0.5 mg/kg; Local pipette delivery; 14 days) has insecticidal, insecticidal and acaricidal activities in cattle <sup>[2]</sup>.

Pharmacokinetic Analysis in cattle<sup>[1]</sup>

Route	Dose ( $\mu\text{g}/\text{kg}$ )	$K_{el}$ ( $\text{day}^{-1}$ )	$t_{1/2}$ (day)	$T_{max}$ (day)	$C_{max}$ (ng/mL)	$\text{AUC}_{0-t}$ (ng day $\text{mL}^{-1}$ )	$\text{AUC}_{0-\infty}$ (ng day $\text{mL}^{-1}$ )	$\text{AUC}_{0-t}/\text{AUC}_{0-\infty}$
s.c.	200	0.267	2.959	1.333	47.15	228.08	240.50	0.947

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Infective nematode or chorioptes bovis treated male Jersey calves <sup>[2]</sup>
Dosage:	0.08, 0.16, 0.2, 0.24 and 0.5mg/kg
Administration:	Delivered topically from the tailhead to the withers at skin level via a pipette; 14 days
Result:	Produced maximal or near maximal efficacy against most of the adult endoparasites with the exception of <i>T. colubriformis</i> (87%) and <i>C. oncophora</i> (88%) at lowest dosage (0.08 mg/kg). Produced $\geq 95\%$ control at all dosage levels by day 14 post-treatment and was maintained at or near this efficacious level for the 6-week duration of the trial.

**REFERENCES**

[1]. Samy A, et al. Eprinomectin: a derivative of ivermectin suppresses growth and metastatic phenotypes of prostate cancer cells by targeting the  $\beta$ -catenin signaling pathway. *J Cancer Res Clin Oncol.* 2023 Sep;149(11):9085-9104.

---

[2]. do Nascimento CG, et al. Injectable eprinomectin for cattle: Tick efficacy and pharmacokinetics. J Vet Pharmacol Ther. 2020 Mar;43(2):171-178.

[3]. Shoop WL, et al. Eprinomectin: a novel avermectin for use as a topical endectocide for cattle. Int J Parasitol. 1996 Nov;26(11):1237-42.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite F, Monmouth Junction, NJ 08852, USA